At Mayo Clinic, researchers have produced one of the rare earth materials in nano size and established non-toxicity of the material for human applications. Additionally they have shown the material induces endothelial cell growth and produces new blood vessels. OmegaGenesis is developing applications based on these unique characteristics of nano materials for proactive maintenance of the human body.
OmegaGenesis through its collaboration with Mayo Clinic has retained exclusive license to further test angiogenesis characteristics of these nano rods and develop products. The agreement includes existing intellectual property and a commitment to ongoing collaborative research projects in early-development stages at Mayo Clinic.
In addition to licensing technology and patents to OmegaGenesis, Mayo Clinic and OmegaGenesis scientists will cooperate in conducting lab tests.
Oostur Raza, CEO of OmegaGenesis, said: “Our collaboration with Mayo Clinic is an example of a strategically important long-term relationship. As a result of this research and product development collaboration, fundamental research conducted by Mayo Clinic is used by OmegaGenesis in the product development process and marketplace applications.”